Halozyme, Inc.

Daniel Edward Vaughn

Gregory Ian Frost

Igor Bilinsky

Barry Sugarman

H Michael Shepard

Ge Wei

Donghyun Kim

Lei Huang

Francois Nicol

Tzung-Horng Yang

Michael James Labarre

Christopher L Caster

Douglas Boyer Muchmore

Provided are compositions that are stable formulations of a hyaluronan-degrading enzyme or are stable co-formulations of a fast-acting insulin and a hyaluronan degrading enzyme, including a recombinant human PH20 (rHuPH20).

Stable formulations of a hyaluronan-degrading enzyme

Provided are methods for control of post-prandial glucose in diabetic subjects by administering a fast-acting insulin analog and a hyaluronidase degrading enzyme. The fast-acting insulin analog and a hyaluronidase are administered between 15 minutes before the meal and 30 minutes after commencing the meal.

Method for control of post-prandial glucose

Super fast-acting insulin compositions

Provided are combinations, compositions and kits containing an fast-acting insulin composition and a hyaluronan degrading enzyme composition formulated for parenteral administration. Such products can be used in methods of treating insulin-treatable diseases or conditions. Also provided are methods for administration of a fast-acting insulin and a hyaluronan degrading enzyme.

Growing community of inventors

Encinitas, CA, United States of America

Daniel Edward Vaughn